Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• 2026 Annual Meeting scheduled for June 9, 2026, with voting rights for shareholders of record as of April 22, 2026.

• Strong first quarter 2026 results with $177 million in revenue, a 5% increase year-over-year, and $40.2 million in Adjusted EBITDA.

• The 5x30 strategy, launched in January 2025, focuses on five pillars: patients served, product revenue, profitability, pipeline development, and partnerships.

• Since the 5x30 launch, stock price increased over 30%, with record 2025 revenues of $726.4 million and GAAP gross margin of 79.4%.

• Board urges shareholders to vote for the company’s nominees and against DOMA’s proposed board changes.

Voting matters and shareholder proposals

• Shareholders are asked to vote for three board nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans.

• Board unanimously recommends voting “FOR” the company’s nominees on the BLUE proxy card.

• DOMA Perpetual Capital Management proposes three alternative nominees and a plan involving cost cuts, pipeline discontinuation, CEO replacement, and a potential sale.

Board of directors and corporate governance

• Board highlights the qualifications of its nominees and criticizes DOMA’s candidates as lacking public company board experience.

• Board warns that DOMA’s plan could reduce board oversight quality and disrupt strategic progress.